5,455 results on '"AbbVie"'
Search Results
2. A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
3. Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)
4. A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
5. Imaging Apoptosis for Lymphoma Treatment Response
6. Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
7. Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
8. Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
9. An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease
10. A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
11. Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
12. Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)
13. Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
14. Epcoritamab and Rituximab for First-line Follicular Lymphoma
15. Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
16. Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
17. MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
18. Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
19. Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1)
20. Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
21. Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
22. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
23. A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
24. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)
25. A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
26. Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
27. A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
28. A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)
29. Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)
30. Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)
31. First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)
32. Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
33. Response to PARP Inhibitor Predicted by the RAD51 Assay (REPAIR)
34. Ibrutinib + Venetoclax in Untreated WM
35. Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
36. A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
37. Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
38. Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses
39. TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
40. Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease (CBT)
41. A Study of Virtual Reality and Linaclotide for IBS-C (IBSC-VR)
42. Venetoclax in Patients With MDS or AML in Relapse After AHSCT
43. Venetoclax Basket Trial for High Risk Hematologic Malignancies
44. A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
45. OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO
46. A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
47. Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
48. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
49. Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
50. Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.